uPA-derived peptide, Å6 is involved in the suppression of lipopolysaccharide-promoted inflammatory osteoclastogenesis and the resultant bone loss

Yosuke Kanno 1, Chihiro Maruyama 1, Ayaka Matsuda 1, & Akira Ishisaki 2

1Faculty of Pharmaceutical Science, Department of Clinical Pathological Biochemistry, Doshisha Women’s Collage of Liberal Arts, Kyoto, Japan
2Department of Biochemistry, Iwate Medical University School of Dentistry, Morioka, Iwate, Japan

Keywords
Bone loss, osteoclasts, uPA-derived peptide Å6

Abstract

Introduction: Chronic inflammatory diseases such as rheumatoid arthritis and periodontitis frequently cause bone destruction. Inflammation-induced bone loss results from the increase of bone-resorbing osteoclasts. Recently, we demonstrated that urokinase type plasminogen activator (uPA) suppressed lipopolysaccharide (LPS)-inflammatory osteoclastogenesis through the adenosine monophosphate-activated protein kinase (AMPK) pathway, whereas its receptor (uPAR) promoted that through the Akt pathway.

Methods: We investigated the effects of uPA-derived peptide (Å6) in the LPS-induced inflammatory osteoclastogenesis and bone destruction.

Results: We found that Å6 attenuated inflammatory osteoclastogenesis and bone loss induced by LPS in mice. We also showed that Å6 attenuated the LPS-promoted inflammatory osteoclastogenesis by inactivation of NF-κB in RAW264.7 mouse monocyte/macrophage lineage cells. Furthermore, we showed that Å6 attenuated the Akt phosphorylation, and promoted the AMPK phosphorylation.

Conclusion: Å6 is involved in the suppression of LPS-promoted inflammatory osteoclastogenesis and bone destruction by regulating the AMPK and Akt pathways. These findings provide a basis for clinical strategies to improve the bone loss caused by inflammatory diseases.
molecular mechanism of Å6 remains to be clarified, the inhibition of uPA and uPAR interaction by Å6 may affect the amelioration of various diseases.

We herein reported the effects of uPA-derived peptide, Å6 on the lipopolysaccharide (LPS)-induced inflammatory OC formation and the resultant bone loss.

Material and Methods

The animal experiments in this study were approved by the Animal Research Committee of Doshisha Women’s College of Liberal Arts (Approval ID: Y15-025). All experiments were performed in accordance with relevant guidelines and regulations.

Reagents

LPS (from Escherichia coli 0111:B4) was purchased from Sigma–Aldrich (St. Louis, MO). Å6 peptide (KPSSPPEE) was synthesized by GL Biochem (Shanghai, China).

Animals

C57B6J mice littermates were housed in groups of two to five in filter-top cages with a fixed 12 h light, 12 h dark cycle.

Bone destruction by the administration of LPS in mice

LPS (25 mg/kg) and Å6 (50 mg/kg) were administered subcutaneously into the shaved back of the male mice. The administration was carried out weekly for up to 4 weeks.

Bone histology

Bone histomorphometry of femurs in male mice were performed as previously described [12]. Each femur was removed and fixed in 4% paraformaldehyde for 2 days, and then demineralized with 10% EDTA for 14 days before embedding in paraffin. Paraffin-embedded tissue was serially sectioned at 4–7 µm distances. Then, the sections were stained with TRAP by using TRAP kit (Sigma–Aldrich). For the quantitative evaluation of the intensity of TRAP-staining in decalcified sections of femurs from the mice, the TRAP-stained images obtained from separate fields on the specimens were analyzed by using ImageJ 1.43u.

Measurement of bone mineral density

Bone mineral density (BMD) was measured as previously described [11, 22]. The BMD of femurs from mice at the indicated time was evaluated by using peripheral quantitative computed tomography with a fixed X-ray fan beam of 50-µm spot size, at 1 mA and 50 kVp (LaTheta LCT-100S; Aloka, Tokyo, Japan).

Cell culture and OC differentiation

RAW264.7 mouse monocyte/macrophage lineage cells were maintained in α-MEM supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO₂/95% air. OC formation was induced as previously described [11, 12]. RAW 264.7 cells were cultured for 3 days with LPS (1 μg/ml) and M-CSF (100 ng/ml) in the absence or presence of Å6 (100 μM) in 48-well plates.

siRNAs study

RAW 264.7 cells were transfected with uPA or uPAR siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. A nonspecific siRNA (Santa Cruz Biotechnology) was employed as the control.

Western blot analysis

Western blot analysis was performed as previously described [23]. Cells were washed twice with cold PBS, harvested, and then sonicated in lysis buffer containing 10 mM Tris–HCl buffer (pH 7.5), 1% SDS, 1% Triton X-100, and a protease inhibitor cocktail (Roche, Mannheim, Germany). The protein concentration in each lysate was measured using a BCA protein assay kit (Pierce, Rockford, IL). Proteins in the supernatant were separated by electrophoresis on 10% SDS-polyacrylamide gels and transferred to a PVDF membrane. We detected expressions of TRAP, NFATc1, IkBα, uPA, uPAR, GAPDH, phospho-AMPK, AMPK, phospho-Akt, Akt by using anti-TRAP antibody (Santa Cruz Biotechnology, Dallas, TX), anti-NFATc1 antibody (Santa Cruz Biotechnology), anti-IkBα antibody (IMGENEX, San Diego, CA), anti-uPA antibody (Santa Cruz Biotechnology), anti-uPAR antibody (Santa Cruz Biotechnology), anti-GAPDH antibody (Sigma–Aldrich), anti-phospho-AMPK antibody (Cell Signaling Technology, Danvers, MA), anti-AMPK antibody (Cell Signaling Technology), anti-phospho-Akt antibody (Cell Signaling Technology), anti-Akt antibody (Cell Signaling Technology) followed incubation with horseradish peroxidase-conjugated antibody to rabbit IgG (Amersham Pharmacia Biotech, Uppsala, Sweden).

Dual luciferase reporter assay

Dual luciferase reporter assay was performed as previously described [11]. pGLA.32 (luc2P/NF-κB/Hygro) vector contains five copies of NF-κB response element (NF-κB–RE) that
derives transcription of the luciferase reporter gene luc2P (Promega, Madison, WI, USA). RAW264.7 cells were co-transfected with pGL4.32 (luc2P/NF-κB/Hygro) vector and the internal control vector pGL4.74 (hRluc/TK) using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s protocol. At 24 h post-transfection, the cells were stimulated with described reagents, and then assayed for luciferase activity using the Dual-Glo luciferase assay system (Promega) according to the manufacturer’s protocol.

ELISA

RAW 264.7 cells were cultured for 24 h with LPS (1 μg/ml). After the indicated incubation periods, the conditioned medium was collected, and the TNF-α in the medium was then measured using a TNF-α mouse antibody pair (Invitrogen). The absorbance of the ELISA samples was measured at 450 nm using Multiskan JX (Thermo Labsystems, Waltham, MA).

Statistical analysis

All data are expressed as mean ± SEM. The significance of the effects of each treatment (p < 0.05) was determined by analysis of variance [24] followed by the least significant difference test.

Results

Å6 attenuated inflammatory osteoclastogenesis and bone destruction induced by LPS in mice

To clarify the effects of Å6 in the inflammatory osteoclastogenesis and bone destruction, we examined the bone mineral...
density (BMD) in the mice by the administration of lipo-polysaccaride (LPS), which is a well-known pathogen of inflammatory bone loss [25]. Å6 attenuated the decrease of BMD induced by LPS (Fig. 1A). Additionally, Å6 attenuated the increase of TRAP-positive area induced by LPS (Fig. 1B and C).

Å6 attenuated OC differentiation of macrophage RAW264.7 cells promoted by LPS

We also examined that the effects of Å6 in LPS-induced the OC differentiation of RAW264.7 cells. RAW264.7 cells simultaneously treated with LPS and M-CSF (Fig. 2A, center panel) looked more clearly positive against TRAP staining than the cells treated with M-CSF alone (Fig. 2A, left panel), but did not appear to be typically and predominantly enlarged multi-nuclear cells containing more than three nuclei in each cell like as maturely differentiated OCs stimulated with LPS and M-CSF. In addition, the cell number of TRAP-positive and enlarged

Figure 2. Å6 attenuated OC differentiation of macrophage RAW264.7 cells promoted by LPS. RAW264.7 cells were cultured for 3 days in the absence or presence of LPS (1 µg/ml), M-CSF (100 ng/ml), or Å6 (100 µM) as indicated. (A) TRAP-staining was performed to detect OC differentiation. Scale bar = 100 µm. (B) The expression of NFATc1 and TRAP in RAW264.7 cells was examined by a Western blot analysis. The histogram on the right panel shows quantitative representations of NFATc1 or TRAP obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). The data represent the mean ± SEM. *p < 0.01, **p < 0.05.

Figure 3. Å6 attenuated TNF-α secretion induced by LPS from macrophage RAW264.7 cells. RAW264.7 cells were cultured for 24 h in the absence or presence of LPS (1 µg/ml) or Å6 (100 µM) as indicated. The TNF-α content in the conditioned media of RAW264.7 cells was determined by using ELISA as described in Materials and Methods (n = 3). The data represent the mean ± SEM. **p < 0.05
RAW264.7 cells under the treatment with LPS and M-CSF was moderately decreased by administration of Å6 (Fig. 2A, right panel). Additionally, the stimulation with LPS and M-CSF more clearly induced the expression of OC markers, NFATc1 and TRAP than stimulation with M-CSF alone (Fig. 2B). In addition, the LPS-promoted OC differentiation of RAW264.7 cells under the M-CSF treatment was clearly suppressed by administration of Å6. These data suggest that Å6 treatment attenuated the LPS-promoted OC differentiation of macrophage under the M-CSF treatment.

Å6 attenuated TNF-α secretion induced by LPS from macrophage RAW264.7 cells

It has been reported that LPS-stimulated osteoclastogenesis is mediated by TNF-α [26, 27]. To clarify the effects of Å6 in the LPS-induced TNF-α production, we examined that the TNF-α production in RAW264.7 cells. Å6 attenuated the LPS-induced TNF-α secretion from RAW264.7 cells (Fig. 3).

Å6 attenuated NF-κB activation induced by LPS in macrophage RAW264.7 cells

We examined the effects of Å6 on the LPS-induced NF-κB transcriptional activity through the use of a functional promoter assay with NF-κB-responsive element. Å6 attenuated the LPS-induced NF-κB activation (Fig. 4A). We also confirmed that Å6 attenuated the LPS-induced IκBα degradation (Fig. 4B). These data strongly suggest that Å6 inhibited the LPS-activated NF-κB signaling.

Å6 inhibited the Akt pathway, but activated the AMPK pathway

It has been reported that the Akt pathway induces OC differentiation [28, 29]. Conversely, adenosine monophosphate-activated protein kinase (AMPK) acts as a negative regulator during OC differentiation [30]. Therefore, we examined whether or not Å6 is associated with the Akt and AMPK pathways in RAW264.7 cells. We showed that Å6 attenuated the Akt phosphorylation, but promoted the AMPK phosphorylation (Fig. 5A). Next, we examined that the effects of AMPK inhibitor, compound C [31] in the Å6-attenuated the OC differentiation induced by LPS. Compound C inhibited the Å6-attenuated OC differentiation of RAW264.7 cells induced by LPS (Fig. 5B). Compound C also inhibited the Å6-attenuated the expression of OC markers, NFATc1 and TRAP induced by LPS (Fig. 5C). Furthermore, compound C inhibited the Å6-attenuated the TNF-α production induced by LPS (Fig. 5D).

No effects of Å6 on the LPS-induced inflammatory OC differentiation in the uPA or uPAR knockdown conditions

In previous study, we demonstrated that uPA knockdown promoted the LPS-induced OC differentiation [11]. Conversely, uPAR knockdown attenuated them [12]. Here, we examined that the effects of Å6 on the LPS-induced OC differentiation in the uPA or uPAR knockdown condition. First, we confirmed that uPA siRNA suppressed the uPA expression but control siRNA did not at protein level in the RAW264.7 cells (Fig. 6A). Å6 inhibited the LPS-induced OC
differentiation, TNF-α production, and IκBα degradation in the control condition, whereas Å6 had no effects on them in the uPA knockdown condition (Fig. 6B–E). Next, we examined that the effects of Å6 on the LPS-induced OC differentiation in the uPAR knockdown condition. We confirmed that uPAR siRNA suppressed the uPAR expression but control siRNA did not at protein level in the RAW264.7 cells (Fig. 6F). Å6 inhibited the LPS-induced OC differentiation and TNF-α production in the control condition, whereas Å6 had no effects on them in the uPAR knockdown condition (Fig. 6G–I).

**Discussion**

We herein showed the uPA-derived peptide, Å6 attenuated LPS-induced inflammatory osteoclastogenesis and bone loss in mice (Fig. 1). We also showed that Å6 attenuated the LPS-promoted OC differentiation (Fig. 2). Furthermore, Å6 attenuated the production of TNF-α (Fig. 3), which is positively associated with the LPS-induced OC differentiation [26, 27]. These data strongly suggest that Å6 is involved in the suppression of LPS-induced inflammatory osteoclastogenesis and bone loss by attenuation of secretion of the inflammatory cytokine from macrophages that homed into the LPS-induced inflammatory tissue.

We previously demonstrated that uPA-activated AMPK attenuated the LPS-induced NF-κB activation, and is involved in the suppression of LPS-induced osteoclastogenesis and bone loss [11]. Conversely, uPAR-activated Akt is involved in the promotion of LPS-induced inflammatory osteoclastogenesis and bone loss [12]. We herein showed that Å6 activated the AMPK signaling
Figure 6. No effects of Å6 on the LPS-induced inflammatory OC differentiation in the uPA or uPAR knockdown conditions. (A) Status of uPA expression in RAW264.7 cells transfected with control or uPA siRNA was examined by a Western blot analysis. The histogram on the bottom panel shows quantitative representations of uPA obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). (B and C) Firstly, either control or uPA siRNA RAW264.7 cells were cultured for 3 days in the absence or presence of LPS (1 μg/ml), M-CSF (100 ng/ml), or Å6 (100 μM) as indicated. (B) TRAP-staining was performed to detect OC differentiation. Scale bar = 100 μM. (C) The expression of TRAP and NFATc1 in RAW264.7 cells with control or uPA siRNA was examined by a Western blot analysis. The histogram on the right panel shows quantitative representations of NFATc1 or TRAP obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). (D) RAW264.7 cells were cultured with either control or uPA siRNA for 24 h in the absence or presence of LPS (1 μg/ml) or Å6 (100 μM) as indicated. The TNF-α content in the conditioned media of RAW264.7 cells transfected with control or uPA siRNA was determined by using ELISA as described in Materials and Methods (n = 3). (E) RAW264.7 cells were pretreated with Å6 (100 μM) for 30 min and then stimulated with LPS (1 μg/ml) for 15 min. Degradation of IkBa was evaluated by a Western blot analysis. The histogram on the bottom panel shows quantitative representations of IkBa obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). (F) Status of uPAR expression in RAW264.7 cells transfected with control or uPAR siRNA was examined by a Western blot analysis. The histogram on the bottom panel shows quantitative representations of uPAR obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). (H and I) Firstly, either control or uPAR siRNA RAW264.7 cells were cultured for 3 days in the absence or presence of LPS (1 μg/ml), M-CSF (100 ng/ml), or Å6 (100 μM) as indicated. (G) TRAP-staining was performed to detect OC differentiation. Scale bar = 100 μM. (H) The expression of TRAP and NFATc1 in RAW264.7 cells with control or uPAR siRNA was examined by a Western blot analysis. The histogram on the right panel shows quantitative representations of NFATc1 or TRAP obtained from densitometry analysis after normalization to the levels of GAPDH expression (n = 3). (I) RAW264.7 cells were cultured with either control or uPAR siRNA for 24 h in the absence or presence of LPS (1 μg/ml) or Å6 (100 μM) as indicated. The TNF-α content in the conditioned media of RAW264.7 cells transfected with control or uPAR siRNA was determined by using ELISA as described in Materials and Methods (n = 3). *p < 0.01, **p < 0.05, NS, not significant.
and attenuated the LPS-induced NF-κB activation (Fig. 4). We also showed that the inhibition of AMPK inhibited the Å6-attenuated OC differentiation induced by LPS (Fig. 5B and C). These data suggest that the Å6-attenuated inflammatory osteoclastogenesis is associated with the AMPK activation. On the other hand, Å6 inhibited the Akt signaling (Fig. 5A). The activation of Akt is known to inhibit the AMPK pathway [32]. It has been reported that uPA promotes the Akt activation [33], and the down-regulation of uPA inhibits the Akt signaling [34, 35]. In addition, we previously demonstrated that uPAR deficiency or uPAR blocking attenuated the Akt pathway [8, 12, 36]. Here, we demonstrated that Å6 inhibited the LPS-induced OC differentiation, and TNF-α production in the control condition, whereas Å6 had no effects on them in the uPA or uPAR knockdown conditions (Fig. 6). These results suggested that Å6 functioned as an attenuator of LPS-induced osteoclastogenesis through the disruption of interaction between uPA and uPAR.

Thus, LPS induced NF-κB activation, resulting in inflammatory osteoclastogenesis and bone destruction. On the other hand, uPAR and uPA-activated plasmin activated the Akt and AMPK pathways, respectively. In addition, the uPAR-induced Akt activation inhibited AMPK pathway. Å6 attenuated the uPAR-activated Akt pathway, possibly resulting in the upregulaton of AMPK activation. The resultant suppression of NF-κB activity inhibited inflammatory osteoclastogenesis and bone destruction (Fig. 7).

Å6 has multiple functions, such as inhibition of angiogenesis, cell growth, cell migration, cell invasion [13]. Angiogenesis, cell growth, cell migration, and cell invasion are known to link to inflammatory bone destruction [37, 38]. These functions of Å6 may also affect the suppression of inflammatory osteoclastogenesis and bone loss. Furthermore, it has been reported that Å6 was no toxicity in Phase 1 and 2 clinical trials [18–21], Å6 might be available for the therapy of inflammatory bone destruction.

In conclusion, uPA-derived peptide, Å6 is involved in the suppression of LPS-promoted inflammatory osteoclastogenesis and the resultant bone loss. These findings provide a basis for therapeutic strategies for the inflammatory bone disease.

Authors’ Contributions

YK conceived and designed the experiments. YK, CM, AM, AI were involved in the experiments. YK analyzed the data. YK and AI wrote the manuscript.

Acknowledgments

This study was supported by JSPS KAKENHI grants-in-aid for Scientific Research (C: 25460078 to Y. Kanno).

Conflict of Interest

All authors state that they have no conflicts of interest.

References

1. Braaten, J. V., S. Handt, W. G. Jerome, J. Kirkpatrick, J. C. Lewis, and R. R. Hantgan. 1993. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 81:1290–1299.
2. Ragno, P. 2006. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell. Mol. Life Sci. 63: 1028–1037.

3. Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932–943.

4. Mondino, A., and F. Blasi. 2004. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 25:450–455.

5. Del Rosso, M., F. Margheri, S. Serrati, A. Chilli, A. Laurenzana, and G. Fibbi. 2011. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr. Pharm. Des. 17:1924–1943.

6. Smith, H. W., and C. J. Marshall. 2010. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11:23–36.

7. Kanno, Y., A. Kaneiwa, M. Minamida, M. Kanno, K. Tomogane, K. Takeuchi, K. Okada, S. Ueshima, O. Matsuho, and H. Matsuno. 2008. The absence of uPAR is associated with the progression of dermal fibrosis. J. Invest. Dermatol. 128:2792–2797.

8. Kanno, Y., H. Matsuno, E. Kawashita, K. Okada, H. Suga, S. Ueshima, and O. Matsuho. 2010. Urokinase-type plasminogen activator receptor is associated with the development of adipose tissue. Thromb. Haemost. 104:1124–1132.

9. Deppe, H., B. Hohlweg-Majert, F. Höhlze, M. R. Kesting, S. Wagenpfel, K. D. Wolff, and M. Schmitt. 2010. Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue. Quintessence Int. 41:165–171.

10. Baran, M., L. N. Möllers, S. Andersson, I. M. Jonsson, A. K. Ekwall, J. Bjersing, A. Tarkowski, and M. Bokarewa. 2009. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J. Cell. Mol. Med. 13:3797–3808.

11. Kanno, Y., A. Ishisaki, E. Kawashita, H. Kuretake, K. Ikeda, and O. Matsuho. 2016. UPA attenuated LPS-induced inflammatory osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK axis. Int. J. Biol. Sci. 12:63–71.

12. Kanno, Y., A. Ishisaki, M. Miyashita, and O. Matsuho. 2016. The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin β3/Akt pathway. Immum. Inflammm. Dis. 4:338–349.

13. Gao, Y. H., and M. Yamaguchi. 2000. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. U. S. A. 97:8484–8489.

14. Boyd, D. D., S. J. Kim, H. Wang, T. R. Jones, and G. E. Gallick. 2003. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am. J. Pathol. 162:619–626.

15. Mishima, K., A. P. Mazar, A. Gown, M. Skelly, X. D. Ji, X. D. Wang, T. R. Jones, W. K. Cavenee, and H. J. Huang. 2000. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. U. S. A. 97:8484–8489.

16. McGuire, P. G., T. R. Jones, N. Talarico, E. Warren, and A. Das. 2003. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target. Invest. Ophthalmol. Vis. Sci. 44:2736–2742.

17. Koh, H. J., K. Bessho, L. Cheng, D. U. Bartsch, T. R. Jones, G. Bergeron-Lynn, and W. R. Freeman. 2004. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest. Ophthalmol. Vis. Sci. 45:635–640.

18. van Troostwijk, A. R., D. Lee, T. R. Jones, J. A. Dyck-Jones, M. H. Silverman, G. N. Lam, and S. J. Warrington. 2004. Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. Int. J. Clin. Pharmacol. Ther. 42:253–259.

19. Berkenblit, A., U. A. Matulonis, J. F. Kroener, B. J. Dezube, G. N. Lam, L. C. Cusay, N. Brunner, T. R. Jones, M. H. Silverman, and M. A. Gold. 2005. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol. Oncol. 99:50–57.

20. Ghamande, S. A., M. H. Silverman, W. Huh, K. Behbakht, G. Ball, L. Cusay, S. O. Wirtz, N. Brunner, and M. A. Gold. 2008. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol. 111:89–94.

21. Gold, M. A., W. E. Brady, H. A. Lankes, P. G. Rose, J. L. Kelley, K. De Geest, M. A. Crispens, K. E. Resnick, and S. B. Howell. 2012. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 125:635–639.

22. Kanno, Y., A. Ishisaki, E. Kawashita, N. Chosa, K. Nakajima, T. Nishihara, K. Toyoshima, K. Okada, S. Ueshima, K. Matsushita, et al. 2011. Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function. J. Biol. Chem. 286:8952–8960.

23. Kanno, Y., E. Shu, H. Kanoh, and M. Seishima. 2016. The antifibrotic effect of α2AP neutralization in systemic sclerosis dermal fibroblasts and mouse models of systemic sclerosis. J. Invest. Dermatol. 136:762–769.

24. Makarova, A. M., T. V. Lebedeva, T. Nassar, A. A. Higazi, J. Xue, M. E. Carinato, K. Bdeir, D. B. Cines, and V. Stepanova. 2011. Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase. J. Biol. Chem. 286:23044–23053.

25. Abu-Amer, Y., F. P. Ross, J. Edwards, and S. L. Teitelbaum. 1997. Lipopolysaccharide-stimulated osteoclastogenesis is
mediated by tumor necrosis factor via its P55 receptor. J. Clin. Invest. 100:1557–1565.

26. Islam, S., F. Hassan, G. Tumurkhuu, J. Dagvadorj, N. Koide, Y. Naiki, I. Morii, T. Yoshida, and T. Yokochi. 2007. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem. Biophys. Res. Commun. 360:346–351.

27. Lam, J., S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481–1488.

28. Moon, J. B., J. H. Kim, K. Kim, B. U. Youn, A. Ko, S. Y. Lee, and N. Kim. 2012. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol. 188:163–169.

29. Cao, H., K. Zhu, L. Qiu, S. Li, H. Niu, M. Hao, S. Yang, Z. Zhao, Y. Lai, J. L. Anderson, et al. 2013. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J. Biol. Chem. 288:30399–30410.

30. Lee, Y. S., Y. S. Kim, S. Y. Lee, G. H. Kim, B. J. Kim, S. H. Lee, K. U. Lee, G. S. Kim, S. W. Kim, and J. M. Koh. 2010. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 47:926–937.

31. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167–1174.

32. Kovacic, S., C. L. Soltsy, A. J. Barr, I. Shiojima, K. Walsh, and J. R. Dyck. 2003. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 278:39422–39427.

33. Tang, C. H., M. L. Hill, A. N. Brunwell, H. A. Chapman, and Y. Wei. 2008. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. J. Cell Sci. 121:3747–3756.

34. Chandrasekar, N., S. Mohanam, M. Gujrati, W. C. Olivero, D. H. Dinh, and J. S. Rao. 2003. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 22:392–400.

35. Gondi, C. S., N. Kandhukuri, D. H. Dinh, M. Gujrati, and J. S. Rao. 2007. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int. J. Oncol. 31:19–27.

36. Kanno, Y., A. Kuroki, M. Minamida, A. Kaneiwa, K. Okada, K. Tomogane, K. Takeuchi, S. Ueshima, O. Matsuo, and H. Matsuno. 2008. The absence of uPAR attenuates insulin-induced vascular smooth muscle cell migration and proliferation. Thromb. Res. 123:336–341.

37. Pap, T., and O. Distler. 2005. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum. 52: 1346–1348.

38. Kim, H. J., J. Park, S. K. Lee, K. R. Kim, K. K. Park, and W. Y. Chung. 2015. Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer. J. Pathol. 237: 520–531.